Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Direxion Daily CSI China Internet Bull 2X Shares (CWEB) vs DexCom, Inc. (DXCM) Price & Performance

Direxion Daily CSI China Internet Bull 2X SharesTrade
DexCom, Inc.Trade

Price performance (Past 24H)

Key statistics

Direxion Daily CSI China Internet Bull 2X Shares vs DexCom, Inc. — how do they compare? Direxion Daily CSI China Internet Bull 2X Shares trades at $22.3, while DexCom, Inc. trades at $76.3 (market cap $28.60B). The key difference: DexCom, Inc. is trading nearer its 52-week high, Direxion Daily CSI China Internet Bull 2X Shares nearer its low. Which is the better fit depends on your goals.

CWEBDXCM
Sector
Leveraged / InverseHealth
52-Week High
$60.13$89.53
52-Week Low
$17.70$54.84
Market Cap
$28.60B
Enterprise Value
$27.57B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Direxion Daily CSI China Internet Bull 2X Shares

CWEB trades at $21.61, down 1.46% today, with technical indicators showing a bullish bias from moving averages but a neutral stance from oscillators. The stock lacks recent fundamental data, with key valuation and profitability ratios unavailable. A dividend of $0.09 is scheduled for June 2026, indicating a potential income component.

The outlook is mixed due to incomplete financials; technical strength offers near-term upside potential, but investment decisions require updated earnings and revenue figures. Risks include data gaps and market volatility, warranting caution until fundamental clarity emerges from SEC filings or company announcements.

DexCom, Inc.

DXCM trades at $76.35, up 1.85% today, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 17.93% net income margin and consistent earnings beats. Recent regulatory approvals for G7 15-day CGM in Canada and pediatric clearance for Stelo OTC system highlight growth catalysts. Revenue growth accelerated to $4.66 billion in 2025, up from $4.0 billion in 2024.

DXCM presents a compelling growth story with expanding CGM market access and strong analyst support (80% buy ratings). Key risks include GLP-1 adoption impact on core market and execution of Type 2 non-insulin patient expansion. The stock trades at a premium valuation (P/E 32.76) but offers upside to consensus target of $83.78. Near-term focus on Q2 2026 earnings release July 30.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Direxion Daily CSI China Internet Bull 2X Shares

CWEB is a leveraged ETF that seeks to provide two times (2x) the daily performance of the CSI China Internet Index. It offers magnified exposure to top Chinese internet companies listed on US and Hong Kong exchanges.

Read more on CWEB

About DexCom, Inc.

Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

Read more on DXCM